Manali J. Bhave, MD

Manali Bhave, MD, is Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board-certified in medical oncology and internal medicine, Dr. Bhave specializes in breast oncology. She joined the Glenn Family Breast Center at Winship Cancer Institute in 2018. Prior to her appointment at Winship, she was a clinical instructor at Northwestern University in Chicago.

Dr. Bhave has a special interest in developing new strategies for the treatment of patients with breast cancer. She is an active member of the Breast Cancer Working Group and the Phase I Clinical Trials Unit and collaborates with other Winship members in clinical trials. Her goal is to provide compassionate, personalized, and state-of-the-art care for her patients through the use of both standard-0f-care therapies and clinical trials.

Dr. Bhave graduated summa cum laude from Northwestern University in Chicago in 2007 with a degree in Psychology and Business Institutions prior to earning her medical degree in 2011 from Northwestern University Feinberg School of Medicine. She completed her residency in internal medicine and women’s health at Northwestern University in 2014. She then completed her fellowship in both medical oncology and hematology at the University of Michigan in Ann Arbor in 2017, and served as Chief Fellow there from 2016-2017.

Specialties

Hematology/Oncology

Board Certifications

ABMS Internal Medicine

Fellowships

University of Michigan Health System

Affiliations

Emory

Education & Training

Medical School: Northwestern University
Residency: Northwestern Feinberg School of Medicine

Honors & Awards

Winship Invest Grant Awardee

V Foundation Grant Awardee

Mark Roth Award at University of Michigan

Chief Fellow at University of Michigan for Hematology/Oncology

Publications

Lee RM, Switchenko JM, Ho TB, Arciero CA, Bhave MA, Subhedar PD. "Is Routine Recurrence Score Testing in Patients Older than 70 years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx." Annals of Surgical Oncology. 2019 Oct; 26(10):3152-3158.

Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK. "Systemic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer." Oncotarget. 2018;9(31):22137-22146.

Chae Y, Galvez C, Anker J, Iams W, Bhave M. "Cancer Immunotherapy in Neglected Population: The Current Use and Future of T-cell Mediated Checkpoint Inhibitors in Organ Transplant Patients." Cancer Treatment Review. 2018;63:116-121.

Bhave M, Henry NL, Kidwell K, Lyden A. "Effect of aromatase inhibitor (AI) therapy on sleep and activity patterns in early stage breast cancer." Clinical Breast Cancer. 2017;S1526-8209(17);30624-9.

Bhave M, Henry NL. "Extended Endocrine Therapy: Is 5 Years Enough?" Curr Oncology Reports. 2017;19(3):16.

Bhave M, Shah AN, Akhter N, Rosen ST. "An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity." Curr Opin Oncol. 2014;26(6):590-9.

Bhave M, Akhter N, Rosen ST. "Cardiovascular toxicity of biologic agents for cancer therapy." Oncology (Williston Park). 2014;28(6):482-90.

Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. "Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events." Hepatology. 2012;56(5):1741-50.

Shetty S, Bhave M, Ghosh K. "Challenges of multiple mutations in individual patients with haemophilia." Eur J Haematol. 2011;86(3):185-90.

Shetty S, Bhave M, Ghosh K. "Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options." Autoimmun Rev. 2011;10(6):311-6.

Bhave M, Kalemkerian G. "Non-small Cell Lung Cancer." Oncology Boards Flash Review, Demos Medical. 2017.

Bhave M, Yentz S, Baker L. "Cancer of Unknown Primary." Cancer: Principles & Practice of Oncology. 2018.